Durham, NC, May 16, 2022 (Globe News) – NightHawk Biosciences (NYSE: NHWK), a fully integrated biopharmaceutical company focused on developing primary care and providing strategic, financial and performance improvements for the first quarter. Completed March 31, 2022, March 2022.
Jeff Wolf, CEO of NightHawk, said: NightHawk Biosciences has been renamed: NightHawk Ecosystem includes development pipelines and production capabilities around five major branches: Skunkworx Bio, Heat Biologics, Pelican Therapeutics, Elusys Therapeutics and Scorpion Biological Services.
In addition, we recently completed Elusys Therapeutics (Elusys) strategic findings, which significantly expand the life support space. Elusys ANTHIM®, for the treatment of inhaled anthrax, completes our infectious product portfolio, which includes the RapidVax® platform designed to combat new biological threats. Shortly after our capture of Elusis, we concluded our first international agreement with the Government of Canada to provide ANTHIM® for its national storage. We are now looking for more opportunities to expand abroad.
“At the same time, we will continue to expand our bio-analytical bioproductive capacity. 2/22 We are on track to open our San Antonio facility.
The story continues
Mr. Wolf added. “NightHawk ecology is truly unique among small biopharmaceutical companies. We look forward to hearing more about our growth later this year.
Financial results for the first quarter of 2022
CPRIT expenditures of $ 0.2 million, eligible for the quarter, ended March 31, 2022 and ended March 31, 2021, compared to $ 0.5 million for the quarter. This year’s cut in aid shows the most important expectations. Completion of delivery at the current contract level. AD As of March 31, 2022, we have a $ 1.5 million balance sheet that we have not yet received, but which has cost or covered costs. We will continue to seek non-refundable funding to support ongoing research and development costs.
Research and development costs were $ 3.9 million, compared to March 31, 2022 for the last three months, and $ 3.4 million for March 31, 2021. The increase is mostly clinical level control recommendations: 1 Studies conducted by researchers. HS-130 and research costs related to staff costs, including inventory-based compensation from inventory rewards.
Total administrative expenses ended March 31, 2022 and March 31, 2021 at $ 3.8 million, $ 4.8 million. The offer shows a $ 2.0 million inventory-based compensation shortfall. $ 0.3 million for additional business consulting and professional expenses.
The net loss for NightHawk Biosciences on March 31, 2022 was approximately $ 8.1 million ($ 0.32) over the past three months, with a net loss estimated at $ 7.5 million ($ 0.31) in gravy is. Three months ended 31 March 2021.
AD As of March 31, 2022, the company had approximately $ 84.1 million in cash, cash and short-term investments.
NightHawk Biosciences, Inc. NightHawk Biosciences is a fully integrated biomass pharmaceutical company focusing on innovative medicine from discovery to commercialization. The company will use the integrated ecosystem to accelerate new therapies that improve the immune system by breaking down barriers to the development of traditional medicine. It enables us to present our ideas effectively, efficiently and extraordinarily efficiently.
For more information about the company and its partners, visit www.nighthawkbio.com or follow us on Twitter.
Opinion: This exemption contains statements that can be found in the 1995 Privacy Act. In some cases, forward-looking statements can be identified by words such as “power”, “should”, “possible”, “next”. . ‘,’ Waits’, ‘Waits’,’ Purpose ‘,’ Plans’, ‘Believe’, ‘Evaluate’ and similar expressions and advertisements like RapidVax® platform. In light of biological threats, NightHawk is looking for more ways to expand. ANTHIM® Overseas Distribution, NightHawk, works as an Employment Contract Development and Manufacturing Company (CDMO) to support other biopharmaceutical companies during its second quarter opening in San Antonio, and will provide further updates on the development of NightHawk. By the end of this year, we will continue our efforts to secure significant future funding for future research and development costs. Some of the factors that could change the outcome are: the ability to keep the company going under the NightHawk banner, successfully integrate Elusys, and expand ANTHIM® overseas sales while the NightHawk and Elusys business. Successful, NightHawk Successful as CDMO, NightHawk and dddddddddddddddh show confidence and efficiency. If available, the ability to complete on time, the desired result, the benefits of continued registration as expected, obtaining a regulatory license to transfer the product candidates to business or to comply with applicable regulations, indicators of Lt.Hook innovations to market or market, product market acceptance and development; Sales, progress made by competitors to make those products obsolete or not. The NightHawk Annual 10-K Report of the Year, December 10, 2021, Q Annual Q10 Reports and Other Competitive Issues Reported by NightHawk to the SEC The information on this application will be provided only on the date of filing; H NightHawk is under no obligation to update links to this information unless required by law, such as new information, upcoming events or otherwise.
Media and Investor Relations David Waldman +1 firstname.lastname@example.org
UCSF 2021 State University Address: